All In Biotech

Drug Trial Radar · NCT05187884

Neoadjuvant/Adjuvant Trial of Darovasertib in Ocular Melanoma

Last checked: Nov 20, 2026Latest source record: Apr 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

15

Actual

Start

May 3, 2022

Primary completion

Jan 1, 2025

Study completion Nov 1, 2025

Sponsor

Lead sponsor
St Vincent's Hospital, SydneyAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 12, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the feasibility and tolerability of neo-adjuvant/adjuvant Darovasertib on uveal melanoma patients. Who is it for? Patients may be eligible to join this study with high-risk uveal melanoma and planned to undergo enucleation Study details: Eligible patients will undergo up to 4 weeks of treatment with Darovasertib (300mg, twice a day as a starting dose) and once determiend safe then up to 6 months after fulfilling inclusion/exclusion criteria and consent. Select patients will undergo adjuvant treatment for 6 months based on their initial response. It is hoped that this research will provide insight into the safety and tolerability of Darovasertib. Furthermore, it aims to document the pharmacodynamic and pharmacokinectic effects of Darovasertib on uveal melanoma patients.

Conditions

  • Ocular Melanoma

Interventions

  • DarovasertibDrug

    Oral Darovasertib 300 mg tablets twice daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To determine the safety of a up to a 56-day course of Darovasertib via clinical assessment by CTCAE v5.0 guidelines for adverse event(s)Time frame: 56 days post commencement of investigational product.
  2. Percentage of participants that complete the 56-day treatment period.Time frame: 56 days post commencement of investigational product.

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Kinghorn Cancer Centre, St. Vincent's Hospital

    Sydney, New South Wales, Australia

  • Alfred Hospital

    Melbourne, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.